BioHarvest Sciences, Inc. · NASDAQ:BHST
BioHarvest Sciences — Investor Presentation (March 2022)
37 slides from BioHarvest Sciences's investor presentation, March 2022
Slide 1: March 2022 Corporate Presentation
MARCH 2022 CORPORATE PRESENTATION CSE: BHSC OTC: CNVCF FRANKFURT: 8MV
Slide 2: Forward-looking information disclaimer
The following presentation contains future looking information based on management expectations. Viewers are cautioned that future looking information is subject to risks and uncertainties including the risk that the company will not achieve its production and sales targets as anticipated or that pr
Slide 3: Global Leader in Plant Cell Biology
GLOBAL LEADER IN PLANT CELL BIOLOGY CSE: BHSC OTC: CNVCF FRANKFURT: 8MV
Slide 4: Next Generation Science-Based Therapeutics
BY UNLOCKING THE SECRETS OF CELLULAR PLANT BIOLOGY, WE BRING THE WORLD NEXT GENERATION SCIENCE-BASED futuristic THERAPEUTICS WITH A STRONG IP PORTFOLIO ADDRESSING A CURRENT 500 BILLION DOLLAR MARKET
Slide 5: Mother Nature provides active compounds inefficiently
MOTHER NATURE PROVIDES ACTIVE MEDICINAL COMPOUNDS Resveratrol BUT Cannabinoids Alkaloids MOTHER NATURE PROVIDES THEM INEFFICIENTLY & Flavonoids TECHNOLOGY HAS FAILED TO DELIVER Gossypol Polyphenols INCONSISTENT UNCLEAN HIGH COST DAMAGES THE ENVIRONMENT
Slide 6: Industrial Scale Platform
OUR BIO-PLANT CELLICITATION TECHNOLOGY IS THE ONLY INDUSTRIAL SCALE PLATFORM 100% CONSISTENCY THAT BRINGS PATENTABLE PLANT BASED THERAPEUTIC SOLUTIONS WHICH: OUR ASEPTIC FIVE • MAINTAIN THE ORIGINAL NATURAL CLEANLINESS C’S LOW COST COMPOUND STRUCTURE • ARE FULL SPECTRUM • IS CONSISTENT & REPEATBALE
Slide 7: Bio-Plant CELLicitation Platform
Bio-Plant CELLicitation Platform SELECTION GROWTH ELICITATION + + = UNIQUE, REPEATABLE & PATENTABLE PHYTOCHEMICAL COMPOUNDS
Slide 8: Platform validated across multiple verticals
Our platform mirrors and enhances nature via CELLicitation and we have validated this across multiple verticals Red Grapes Cannabis Pomegranate Olives Full-Spectrum Multiple Minor Cannabinoids together Increase PGG Polyphenol Increase Piceid ( 1,2,3,4,6-pentagalloyl glucose ) Increase Verbascoside R
Slide 9: Biotech leader addressing a ±500 billion USD market
BIOTECH LEADER WITH PROVEN PLATFORM TECHNOLOGY THAT ADRESSES A CURRENT ±500 BILLION USD MARKET OPPORTUNITY $ TGF $ $ $ FFG $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ Nutraceuticals Cannabinoids Botanical Drugs Psychedelics Protein Growth Factors TCM USD 275 BILLION USD 25 BILLION USD 35 BILLION USD 5 BIL
Slide 10: 21 Days vs. 2 Years in nature
Our Bio-Plant CELLicitation Platform Technology Polyphenols Cannabinoids Psychedelics* TCM* Growth Factors* 1 WE TAKE THE 3 STORE THEM 5 BIO-DRYING PLANT ONCE IN CELL BANK 2 ISOLATE THE CELLS WITH 4 BIO-CELLICIT KEY ACTIVE INGREDIENTS 21 Days vs. 2 Years in nature Future Platforms *
Slide 11: VINIA based on red grape cells
VINIA (based on red grape cells) is the first demonstration of the power of our CELLicitation technology Heart health Supports heart health by Blood pressure improving blood flow and Supports blood pressure delivery of oxygen.* already within normal range Increases dilation of arteries and blood ves
Slide 12: Best in Class Verified Review Rating
With a “Best in Class” Verified Review Rating
Slide 13: Customer reviews
William G. Verified Suyer 01/23/22 wo te Energy increase (relevant) —<-er Blood flow/Blood circulation (ifrelevan) ——__— Best thing since sliced bread!! lam am always very wary about taking over the counter herbs. They never work for me. That was until | took Vina! This stuff workstt! | was wonder i
Slide 14: VINIA sold USD 2.4M in 2021
VINIA sold USD 2.4 M in 2021 with > 11,000 direct customers validating its performance and the prospect for Botanical Drug applications Polyphenol Therapeutics Pipeline VINIA® Historical Revenue Growth in USD by Quarter 700,000 Olive Cells Pomegranate Cells 600,000 500,000 +55% 400,000 USD $ +33% 30
Slide 15: VINIA as a botanical drug for blood flow diseases
Allowing VINIA in the future to also be positioned as a botanical drug addressing key BLOOD FLOW related diseases Erectile Gingivitis Metabolic Dysfunction 50% of Adults Syndrome 52% of Men 33% of US Adults ADHD & Raynaud’s Meniere’s NO ADD Disease Disease ADHD 20% of US Kids 5% of US Adults 2% of U
Slide 16: Platform solves botanical drug challenges
Our platform technology solves all Botanical Drug challenges & bottleneck CHALLENGES BIO-PLANT CELLicitation SOLUTION 1 REPEATABILITY 2 PATENTABILITY 3 PURITY FINGERPRINT UNIQUE COMPOSITION, ASEPTIC CONSISTENT TECHNOLOGY PROCESS CONDITIONS MANUFACTURING & UTILITY DRIVING HIGH PATENTABILITY 4 SAFETY
Slide 17: Validated across multiple plant species
THE BIO-CELLicitation PLATFORM HAS BEEN VALIDATED ACROSS MULTIPLE PLANT SPECIES
Slide 18: 13 cycles per year vs 4-6 cycles
Our Bio-Plant CELLicitation Platform Technology Polyphenols Cannabinoids Psychedelics* TCM* Growth Factors* 1 WE TAKE THE 3 STORE THEM 5 BIO-DRYING PLANT ONCE IN CELL BANK 2ISOLATE THE CELLS WITH 4 BIO-CELLICIT KEY ACTIVE INGREDIENTS 13 Cycles per year VS. 4-6 Cycles per year Future Platforms *
Slide 19: Nature vs Bio-Plant CELLicitation
NATURE BIO-PLANT CELLICITATION WITHOUT HAVING TO GROW THE PLANT
Slide 20: Creating unique biological structures
WITHOUT HAVING TO GROW THE PLANT NATURE BIO-PLANT CELLICITATION CREATING UNIQUE BIOLOGICAL STRUCTURES
Slide 21: Creating unique biological structures
WITHOUT HAVING TO GROW THE PLANT NATURE BIO-PLANT CELLICITATION CREATING UNIQUE BIOLOGICAL STRUCTURES
Slide 22: 100-200X the density of trichomes
NATURE BIO-PLANT CELLICITATION 100-200X THE DENSITY OF TRICHOMES VS THE PLANT
Slide 23: We have now produced kilograms
Our technology only grows trichomes at a density the world has never seen before We have now produced Kilograms
Slide 24: Click below for the video
CLICK BELOW FOR THE VIDEO without growing e plant itself
Slide 25: Opportunity to impact major medical conditions
Providing us the opportunity to impact major palliative and other medical conditions
Slide 26: Bio-Plant CELLicitation vs other technologies
BIO-PLANT CELLicitation VS OTHER TECHNOLOGIES Conventional Farming+ extraction Biosynthesis Land use efficiency High Low High Production cost ($/kg) Low High Unknown Capex Low High Medium Production cycle times Low High Semi/Continuous Purity High Low High Consistency High Low High Full spectrum Com
Slide 27: Superior scalability, capital efficiency and ROI
Bio-Plant CELLicitation has Superior SCALABILITY, CAPITAL EFFICIENCY & ROI $3-4M CAPEX + 1200 SQUARE = 20 METRIC TONS > $ 40M METERS OF PER YEAR OF IN POTENTIAL LAND ACTIVE PLANT REVENUE PER BASED YEAR COMPOUNDS
Slide 28: Sustainability is at the core of everything we do
Sustainability is at the 98% CORE of everything we do First Biotech company engaged in the production of Cannabis biomass and cannabinoids to publish an ESG Sustainability Report OUR GROWING PROCESS FOR CANNABIS USES 98% less land 90% less space than traditional than indoor growing outdoor agricultu
Slide 29: Experienced management team
Led by a high-performance experienced management team Ilan Sobel DR. Yochi Hagay DR. Malkit Azachi Michal Sapir CEO CTO VP R&D VP Regulation Affairs Justin Meiklem Alan Rootenberg Kobi Rosenzweig Jarred Turner Head of IR CFO VP Operations VP of E-Commerce
Slide 30: Supported by a team of industry leaders
Supported by a team of industry leaders MEDICAL ADVISORY BOARD EITAN EITAN POPPER STEVEN LEHRER DR RHONA APPLEBAUM DR. DENNIS GOODMAN CANNABIS PIONEER BIOTECH REGULATORY AND SCIENTIFIC AFFAIRS CARDIOLOGIST SCOTT MCCUNE COL CHRIS HADFIELD ADV ROBERTO CHAIT DR DAVID BRADY CONSUMER MARKETING SPACE AND
Slide 31: Best in Class Biotech Capabilities
BUILT Best in Class BIOTECH Capabilities serving Multiple Verticals R&D REGULATION CLINICAL RESEARCH D2C SALES END TO END THE BRAIN MANUFACTURING COMMERCIAL BUSINESS MACHINE DEVELOPMENT/B2B SALES TECHNOLOGY PROCESSES
Slide 32: Best in Class Biotech Capabilities: R&D and clinical
BUILT Best in Class BIOTECH Capabilities serving Multiple Verticals R&D CLINICAL RESEARCH $45M 14 3 INVESTED PATENTS CLINICAL THE BRAIN TRIALS 8 3 SCIENTIFIC PATENTS STUDIES PENDING
Slide 33: Best in Class Biotech Capabilities: manufacturing
BUILT Best in Class BIOTECH Capabilities across Multiple Verticals 2 TON 20+ TONS END TO END PER YEAR PILOT PER YEAR INDUSTRIAL THE BRAIN MANUFACTURING PLANT (CANNABIS) MANUFACTURING FACILITY Patented Custom Custom BIO MEASUREMENT DRYING TECHNOLOGY REACTORS TECHNIQUES TECHNIQUES PROCESSES
Slide 34: High performing commercial machine
High performing commercial machine driving major results REGULATION D2C SALES BUSINESS DEVELOPMENT/B2B SALES COMMERCIAL MACHINE Produced according to FDA Guidelines
Slide 35: Take the Power of our Technology to New Frontiers
Take the Power of our Technology to New Frontiers Produce primary metabolites such as Produce antioxidant compounds that Assess the health impact of 1 premium proteins that are needed to provide required nutrition for humans 2 can help reduce human cellular stress and prevent damage caused by 3 micr
Slide 36: Key Highlights
Key Highlights: Global leader in Plant Cell Biology Innovative and disruptive Biotech Platform Technology opening the gate for patentable Botanical Drugs Validated and proven technology across multiple verticals with significant current revenues High scalability with low capex requirements ($3-4M) a
Slide 37: Global Leader in Plant Cell Biology
GLOBAL LEADER IN PLANT CELL BIOLOGY “Partnering sustainably with nature for the next generation of plant-based therapeutics without growing the plant” Ilan Sobel - CEO BioHarvest Sciences Inc info@bioharvest.com Ilan@bioharvest.com
BioHarvest Sciences — Investor Presentation (March 2022) on 6ix